Macrocyclic Modulators of the Ghrelin Receptor
AssigneeOcera Therapeutics, Inc.
InventorsEric Marsault, Carl St-Louis
Life of this patent
Estimating the term…
Loading patent…
AssigneeOcera Therapeutics, Inc.
InventorsEric Marsault, Carl St-Louis
Estimating the term…
The present invention provides novel conformationally-defined macrocyclic compounds that have been demonstrated to be selective modulators of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). Methods of synthesizing the novel compounds are also described herein. These compounds are useful as agonists of the ghrelin receptor and as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, gastrointestinal disorders, cardiovascular disorders, obesity and obesity-associated disorders, central nervous system disorders, genetic disorders, hyperproliferative disorders and inflammatory disorders.
1-11. (canceled)
A method of treating a gastrointestinal disorder comprising administering to a subject in need thereof an effective amount of a compound having the structure:
A method of treating a subject suffering from a lack of appetite, suppressed appetite, or a disease or disorder that results in decreased food intake comprising administering to a subject in need thereof an effective amount of a compound having the structure:
A pharmaceutically acceptable salt of a compound having the structure:
Dependencies are inferred from the claim text.